


CLAIMS

1. A method for treating a subject for glaucoma, comprising:
administering a therapeutically effective amount of a deprenyl compound to a
5 subject such that the subject is treated for glaucoma.

2. The method of claim 1, wherein the deprenyl compound is represented by the structure:



10 in which

R_1 is hydrogen, alkyl, alkenyl, alkynyl, aralkyl, alkylcarbonyl, arylcarbonyl, alkoxy carbonyl, or aryloxy carbonyl;

R_2 is hydrogen or alkyl;

R_3 is a single bond, alkylene, or $-(\text{CH}_2)_n-\text{X}-(\text{CH}_2)_m$;

15 in which X is O, S, or N-methyl; m is 1 or 2; and n is 0, 1, or 2;

R_4 is alkyl, alkenyl, alkynyl, heterocyclyl, aryl or aralkyl; and

R_5 is alkylene, alkenylene, alkynylene and alkoxylenylene; and

R_6 is C_3 - C_6 cycloalkyl or



20 R_2 and R_4 - R_3 are joined to form, together with the methine to which they are attached, a cyclic or polycyclic group;
and pharmaceutically acceptable salts thereof.

3. The method of claim 2, wherein R_1 is a group that can be removed *in vivo*.

25

4. The method of claim 2, wherein R_1 is hydrogen.

5. The method of claim 2, wherein R_1 is alkyl.

30 6. The method of claim 5, wherein R_1 is methyl.

7. The method of claim 2, wherein R_2 is methyl.

8. The method of claim 2, wherein R_3 is methylene.

35

9. The method of claim 2, wherein R_4 is aryl.


10. The method of claim 2, wherein R_4 is phenyl.

11. The method of claim 2, wherein R_5 is methylene.

12. The method of claim 2, wherein R_6 is




13. The method of claim 2, wherein the deprenyl compound has the structure



wherein R_1 is hydrogen, alkyl, alkenyl, alkynyl, aralkyl, alkylcarbonyl, arylcarbonyl, alkoxy carbonyl, or aryloxy carbonyl.

14. The method of claim 2, wherein the deprenyl compound is represented by the structure:



in which

R_1 is hydrogen, alkyl, alkenyl, alkynyl, aralkyl, alkylcarbonyl, arylcarbonyl, alkoxy carbonyl, or aryloxy carbonyl;

R_2 is hydrogen or alkyl;


R_3 is a bond or methylene; and

R_4 is aryl or aralkyl; or

R_2 and R_4-R_3 are joined to form, together with the methine to which they are attached, a cyclic or polycyclic group;

and pharmaceutically acceptable salts thereof.

15. The method of claim 2, wherein the deprenyl compound is represented by the structure:



in which

R₂ is hydrogen or alkyl;

R₃ is a bond or methylene; and


R₄ is aryl or aralkyl; or

5 R₂ and R₄-R₃ are joined to form, together with the methine to which they are attached, a cyclic or polycyclic group; and

R₅ is alkylene, alkenylene, alkynylene and alkoxylenes;

and pharmaceutically acceptable salts thereof.

10 16. The method of claim 2, wherein the deprenyl compound is represented by the structure:



in which

15 R₁ is hydrogen, alkyl, alkenyl, alkynyl, aralkyl, alkylcarbonyl, arylcarbonyl, alkoxycarbonyl, or aryloxy carbonyl;

A is a substituent independently selected for each occurrence from the group consisting of halogen, hydroxyl, alkyl, alkoxy, cyano, nitro, amino, carboxyl, $-CF_3$, or azido; n is 0 or an integer from 1 to 5;

20 and pharmaceutically acceptable salts thereof.

17. The method of claim 1, wherein the deprenyl compound is (-)-deprenyl.

18. The method of claim 1, wherein the deprenyl compound is (-)-pargyline.

25

19. The method of claim 1, wherein the deprenyl compound is (-)-desmethyldeprenyl.

20. A kit comprising a container of a deprenyl compound and instructions for administering a therapeutically effective amount of the deprenyl compound to a subject such
30 that the subject is treated for glaucoma.